两天近100亿美元!诺和诺德、BMS重磅收购,今年的并购浪潮高过以往。诺和诺德继续通过“买买买”来充盈研发管线。10月9日,诺和诺德与Akero Therapeutics达成收购协议,预付款为47亿美元,加上CVR(或有价值权)合计52亿美元。诺和诺德将获得AKT-268,这是一种治疗MASH(代谢功能障碍相关steatohepatitis)的研究药物,目前处于I期临床阶段。10月15日,诺和诺德...
Source Link两天近100亿美元!诺和诺德、BMS重磅收购,今年的并购浪潮高过以往。诺和诺德继续通过“买买买”来充盈研发管线。10月9日,诺和诺德与Akero Therapeutics达成收购协议,预付款为47亿美元,加上CVR(或有价值权)合计52亿美元。诺和诺德将获得AKT-268,这是一种治疗MASH(代谢功能障碍相关steatohepatitis)的研究药物,目前处于I期临床阶段。10月15日,诺和诺德...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.